These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
67 related articles for article (PubMed ID: 8458616)
1. The effects of glibenclamide on glucose homeostasis and lipoprotein metabolism in poorly controlled type 2 diabetes. Baynes C; Elkeles RS; Henderson AD; Richmond W; Johnston DG Horm Metab Res; 1993 Feb; 25(2):96-101. PubMed ID: 8458616 [TBL] [Abstract][Full Text] [Related]
2. Sustained effects of pioglitazone vs. glibenclamide on insulin sensitivity, glycaemic control, and lipid profiles in patients with Type 2 diabetes. Tan MH; Johns D; Strand J; Halse J; Madsbad S; Eriksson JW; Clausen J; Konkoy CS; Herz M; Diabet Med; 2004 Aug; 21(8):859-66. PubMed ID: 15270789 [TBL] [Abstract][Full Text] [Related]
3. The role of insulin insensitivity and hepatic lipase in the dyslipidaemia of type 2 diabetes. Baynes C; Henderson AD; Anyaoku V; Richmond W; Hughes CL; Johnston DG; Elkeles RS Diabet Med; 1991 Jul; 8(6):560-6. PubMed ID: 1832357 [TBL] [Abstract][Full Text] [Related]
4. The effects of glibenclamide on serum lipids and lipoproteins in type II non-insulin dependent diabetes mellitus. Mughal MA; Maheri WM; Aamir K; Jan M; Ali M J Pak Med Assoc; 1999 Apr; 49(4):89-92. PubMed ID: 10540537 [TBL] [Abstract][Full Text] [Related]
5. The effects of oral hypoglycaemic drugs on serum lipids and lipoproteins in non-insulin-dependent diabetes (NIDDM). Elkeles RS Diabete Metab; 1991 May; 17(1 Pt 2):197-200. PubMed ID: 1936476 [TBL] [Abstract][Full Text] [Related]
6. The effect of sensitisation to insulin with pioglitazone on fasting and postprandial lipid metabolism, lipoprotein modification by lipases, and lipid transfer activities in type 2 diabetic patients. Al Majali K; Cooper MB; Staels B; Luc G; Taskinen MR; Betteridge DJ Diabetologia; 2006 Mar; 49(3):527-37. PubMed ID: 16429317 [TBL] [Abstract][Full Text] [Related]
7. How does glibenclamide lower plasma glucose concentration in patients with type 2 diabetes? Jeng CY; Hollenbeck CB; Wu MS; Chen YD; Reaven GM Diabet Med; 1989; 6(4):303-8. PubMed ID: 2524334 [TBL] [Abstract][Full Text] [Related]
8. Streptozotocin-Treated High Fat Fed Mice: A New Type 2 Diabetes Model Used to Study Canagliflozin-Induced Alterations in Lipids and Lipoproteins. Yu T; Sungelo MJ; Goldberg IJ; Wang H; Eckel RH Horm Metab Res; 2017 May; 49(5):400-406. PubMed ID: 28395380 [TBL] [Abstract][Full Text] [Related]
9. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus. Plosker GL; Figgitt DP Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124 [TBL] [Abstract][Full Text] [Related]
10. Effects of metformin on glucose, insulin and lipid metabolism in patients with mild hypertriglyceridaemia and non-insulin dependent diabetes by glucose tolerance test criteria. Hollenbeck CB; Johnston P; Varasteh BB; Chen YD; Reaven GM Diabete Metab; 1991; 17(5):483-9. PubMed ID: 1752350 [TBL] [Abstract][Full Text] [Related]
11. Insulin resistance is independently associated with postprandial alterations of triglyceride-rich lipoproteins in type 2 diabetes mellitus. Annuzzi G; De Natale C; Iovine C; Patti L; Di Marino L; Coppola S; Del Prato S; Riccardi G; Rivellese AA Arterioscler Thromb Vasc Biol; 2004 Dec; 24(12):2397-402. PubMed ID: 15458975 [TBL] [Abstract][Full Text] [Related]
12. Effect of insulin and sulfonylurea therapy, at the same level of blood glucose control, on low density lipoprotein subfractions in type 2 diabetic patients. Rivellese AA; Patti L; Romano G; Innelli F; Di Marino L; Annuzzi G; Iavicoli M; Coronel GA; Riccardi G J Clin Endocrinol Metab; 2000 Nov; 85(11):4188-92. PubMed ID: 11095452 [TBL] [Abstract][Full Text] [Related]
13. Prospective comparative study in NIDDM patients of metformin and glibenclamide with special reference to lipid profiles. Hermann LS; Karlsson JE; Sjöstrand A Eur J Clin Pharmacol; 1991; 41(3):263-5. PubMed ID: 1748145 [TBL] [Abstract][Full Text] [Related]
15. [Effect of glibenclamide on lipid metabolism in non-insulin-dependent diabetic patients]. Ratzmann KP; Schimke E; Herrmann C; Borngräber G; Meusel K Z Gesamte Inn Med; 1988 Mar; 43(5):122-4. PubMed ID: 3133890 [TBL] [Abstract][Full Text] [Related]
16. Effect of the prostaglandin E1 analog enisoprost on glucose and lipid metabolism in patients with type II diabetes mellitus. Kasim SE; Moran M; Khilnani S; West MA; Jen KL Horm Metab Res; 1992 Apr; 24(4):176-80. PubMed ID: 1601393 [TBL] [Abstract][Full Text] [Related]
17. The effect of glimepiride on pancreatic beta-cell function under hyperglycaemic clamp and hyperinsulinaemic, euglycaemic clamp conditions in non-insulin-dependent diabetes mellitus. Clark HE; Matthews DR Horm Metab Res; 1996 Sep; 28(9):445-50. PubMed ID: 8911981 [TBL] [Abstract][Full Text] [Related]
18. Glyburide enhances the responsiveness of the beta-cell to glucose but does not correct the abnormal patterns of insulin secretion in noninsulin-dependent diabetes mellitus. Shapiro ET; Van Cauter E; Tillil H; Given BD; Hirsch L; Beebe C; Rubenstein AH; Polonsky KS J Clin Endocrinol Metab; 1989 Sep; 69(3):571-6. PubMed ID: 2503533 [TBL] [Abstract][Full Text] [Related]
19. Effects of nateglinide and glibenclamide on postprandial lipid and glucose metabolism in type 2 diabetes. Vakkilainen J; Mero N; Schweizer A; Foley JE; Taskinen MR Diabetes Metab Res Rev; 2002; 18(6):484-90. PubMed ID: 12469362 [TBL] [Abstract][Full Text] [Related]
20. A long-term, randomized, comparative study of insulin versus sulfonylurea therapy in type 2 diabetes. Birkeland KI; Hanssen KF; Urdal P; Berg K; Vaaler S J Intern Med; 1994 Sep; 236(3):305-13. PubMed ID: 8077888 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]